Zevra Therapeutics Files 8-K with Material Agreement
Ticker: ZVRA · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, disclosure, financials
TL;DR
ZEVRA files 8-K, new material agreement signed Feb 26.
AI Summary
On February 26, 2025, Zevra Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial statements and exhibits. Zevra Therapeutics, Inc. was formerly known as KemPharm, Inc. until May 30, 2013.
Why It Matters
This filing indicates a significant development for Zevra Therapeutics, potentially involving a new partnership, acquisition, or other material contract that could impact its business operations and future prospects.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this initial filing warrants a medium risk assessment.
Key Players & Entities
- Zevra Therapeutics, Inc. (company) — Registrant
- February 26, 2025 (date) — Date of Earliest Event Reported
- KemPharm, Inc. (company) — Former Company Name
- May 30, 2013 (date) — Date of Name Change
FAQ
What is the nature of the material definitive agreement entered into by Zevra Therapeutics, Inc. on February 26, 2025?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on February 26, 2025.
What other items are included in this 8-K filing?
This 8-K filing includes a Regulation FD Disclosure and Financial Statements and Exhibits, in addition to the entry into a material definitive agreement.
When did Zevra Therapeutics, Inc. change its name from KemPharm, Inc.?
Zevra Therapeutics, Inc. changed its name from KemPharm, Inc. on May 30, 2013.
What is the principal executive office address for Zevra Therapeutics, Inc.?
The principal executive office address is 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.
What is the SIC code for Zevra Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Zevra Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding ZEVRA THERAPEUTICS, INC. (ZVRA).